SCHEMBL6869271

SCHEMBL6869271

CN1CCN(c2ccc(C(=O)O)c(-c3ccccc3Cl)c2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.50
RAB9A P51151 3/20 0.46
HTR6 P50406 3/20 0.46
NPC1 O15118 2/20 0.46
BRD4 O60885 1/20 0.45
TACR1 P25103 1/20 0.45
HTR3A P46098 1/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ALOX15 P16050 1/20 0.44
CYP2C19 P33261 1/20 0.44
ALDH1A1 P00352 1/20 0.44
SIRT6 Q8N6T7 1/20 0.43
PRKAB2 O43741 1/20 0.43
PRKAG1 P54619 1/20 0.43
PRKAA2 P54646 1/20 0.43
PRKAA1 Q13131 1/20 0.43
PRKAG3 Q9UGI9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6868712 0.86 TACR1 (0.58) L3MBTL1RAB9AHTR6NPC1TACR1
SCHEMBL5340834 0.82 TDP1 (0.56) L3MBTL1RAB9AHTR6NPC1BRD4
SCHEMBL15923279 0.82 RAB9A (0.56) RAB9AHTR6NPC1HTR3AALDH1A1
SCHEMBL4131710 0.75 TACR1 (0.82) TACR1
SCHEMBL1336438 0.75 CHEK1 (0.51) RAB9AHTR6NPC1HTR3ASIRT6
SCHEMBL27320988 0.75 IP6K1 (0.50) RAB9AHTR6NPC1HTR3AALDH1A1
SCHEMBL31536499 0.75 PKM (0.55) RAB9AHTR6NPC1HTR3AALDH1A1
SCHEMBL2913153 0.74 TACR1 (0.57) HTR6TACR1HTR3ACYP1A2CYP3A4
SCHEMBL30263195 0.74 CYP1A1 (0.47) RAB9ANPC1BRD4CYP1A2ALOX15
Toluic Acid SCHEMBL28119604 0.74 HTR3A (0.47) L3MBTL1RAB9AHTR6NPC1TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1171419-B1 BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR HOFFMANN LA ROCHE (CH) 2004-12-29 EP disclosed
US-6552088-B2 2'-methyl-biphenyl-2-carboxylic acid-(3,5-bis-trifluoromethyl-benzyl)-methyl-amide, for example; treating disease related to neurokinin 1 receptor HOFFMANN-LA ROCHE INC. 2003-04-22 US disclosed
US-20020040060-A1 Biphenyl derivatives BOS MICHAEL (CA) 2002-04-04 US disclosed
EP-1171419-A1 BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2002-01-16 EP disclosed
US-6291465-B1 Biphenyl derivatives HOFFMANN-LA ROCHE INC. 2001-09-18 US disclosed
WO-2000053572-A1 BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2000-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040060-A1 Biphenyl derivatives NR1H4, NR1H2, NR1H3 L3MBTL1 1459/4885RAB9A 2043/4885HTR6 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.